Aptose Biosciences Secures $8 Million in Funding to Advance Groundbreaking Cancer Therapies

Aptose Biosciences, a pioneering clinical-stage biotechnology company dedicated to addressing critical unmet needs in hematologic malignancies, has successfully closed an $8 million funding round. This substantial investment will accelerate the development of Aptose’s innovative therapies, including CG-806, a groundbreaking oral mutation-agnostic FLT3/BTK inhibitor. CG-806 is designed to treat patients suffering from certain B-cell malignancies like chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and various forms of non-Hodgkin’s lymphoma (NHL), particularly targeting those who have become resistant or intolerant to existing treatment options. Furthermore, CG-806 is also progressing in clinical development for relapsed or refractory acute myeloid leukemia (AML), focusing on patient populations resistant to currently approved therapies. Alongside CG-806, Aptose is advancing its promising first-in-class MYC Inhibitor, APTO-253, aimed at treating patients with relapsed or refractory AML or myelodysplastic syndrome (MDS). The newly raised capital will not only bolster ongoing clinical trials but also enhance Aptose’s operational capabilities, ensuring a robust pathway toward meeting the urgent needs of patients facing these challenging hematologic malignancies. By investing in pioneering therapies that hold promise for improved patient outcomes, Aptose Biosciences is poised to redefine the treatment landscape for these critical conditions, making significant strides toward a brighter future in oncology.